Immunohistological staining of CD160 in chronic B-cell malignancies. Tissue sections and TMAs were stained with CD160 antibody (10 μg/mL), incubated overnight at 4°C, and revealed using the Super Sensitive Polymer-HRP Detection System (Biogenex). (A-C) Control: a lymph node TMA spot from a patient with CLL without the primary antibody. Magnifications were ×5 (A), ×20 (B), and ×63 (C). (D-F) Positive CD160 staining of a CLL lymph node TMA. Magnifications were ×5 (A), ×20 (B), and ×63 (C). Of the CLL TMA cases, 85 of 88 (96.5%) were CD160⁺. (G-I) Negative CD160 staining of an MCL lymph node on a TMA. Magnifications were ×5 (A), ×20 (B), and ×63 (C). Of the MCL TMA cases, 94 of 97 were CD160⁻. (J-L) Two HCL cases showing typical strong CD160 positivity, a BM trephine (J), and a splenic biopsy. Magnifications were ×43 (K) and ×63 (L).